Skip to content
Search

Latest Stories

Australia to ensure India have 'best' training facilities in quarantine

India will have to abide by Australia's 14-day quarantine requirement ahead of the test series starting in December but arrangements will be made to ensure their players can prepare as well as possible, Cricket Australia (CA) said on Tuesday.

The Indian board's (BCCI) chief Sourav Ganguly told local media earlier this month he hoped Virat Kohli's side could have their quarantine "reduced a bit" before the first test in Brisbane from Dec. 3.


Australia requires international arrivals to isolate in quarantine hotels due to the COVID-19 pandemic, though some have been allowed to pass the period at home due to health reasons.

CA interim chief executive Nick Hockley suggested there was little prospect of India's players having a shorter quarantine.

"It’s widely known and unlikely international travel restriction will have lifted by the time India are due to come into the country," he told reporters on a video call.

"I think the two-week quarantine is pretty well defined. What we’re working on is making sure that within that quarantine environment, the players have got the absolutely the best training facilities so that their preparation for the matches is as optimal as it can possibly be."

Hockley said Australia was closely watching the West Indies tour of England, which has gone off largely without a hitch apart from fast bowler Joffra Archer breach of the team's biosecurity protocols.

The Adelaide Oval, which has an attached hotel, has been seen as a potential venue for India to train safely while in quarantine.

"Whether it's a hotel on-site or hotels in close proximity to venues, it’s about certainly creating that environment where we’re minimising the risk of infections," said Hockley.

"Creating a biosecure environment is the absolute priority because there’s just a huge amount at stake if we’re not able to do that."

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less